Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Consolidated Net Income: 2016-2024

Historic Consolidated Net Income for Denali Therapeutics (DNLI) over the last 9 years, with Dec 2024 value amounting to -$422.8 million.

  • Denali Therapeutics' Consolidated Net Income rose 4.01% to -$114.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$422.7 million, marking a year-over-year increase of 3.58%. This contributed to the annual value of -$422.8 million for FY2024, which is 191.12% down from last year.
  • Per Denali Therapeutics' latest filing, its Consolidated Net Income stood at -$422.8 million for FY2024, which was down 191.12% from -$145.2 million recorded in FY2023.
  • Over the past 5 years, Denali Therapeutics' Consolidated Net Income peaked at $71.1 million during FY2020, and registered a low of -$422.8 million during FY2024.
  • Its 3-year average for Consolidated Net Income is -$298.0 million, with a median of -$326.0 million in 2022.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first spiked by 136.00% in 2020, then plummeted by 508.49% in 2021.
  • Over the past 5 years, Denali Therapeutics' Consolidated Net Income (Yearly) stood at $71.1 million in 2020, then tumbled by 508.49% to -$290.6 million in 2021, then decreased by 12.19% to -$326.0 million in 2022, then surged by 55.45% to -$145.2 million in 2023, then tumbled by 191.12% to -$422.8 million in 2024.